Anavex Announces $10 Million Private Placement of Convertible Debentures

Secures Capital to Execute Clinical Trial Phase 1b/2a in Alzheimer’s Disease and Advance Product Portfolio New York, NY — March 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types…